Skip to content
Search

Latest Stories

AI algorithm that detects brain defects could help treat hard-to-spot epilepsy

A University College London team of researchers has developed an artificial intelligence (AI) programme that can identify minute brain defects or anomalies that lead to epileptic seizures.

The algorithm, used in the Multicentre Epilepsy Lesion Detection project (MELD) and which reports locations of abnormalities in cases of drug-resistant focal cortical dysplasia (FCD) -- a major cause of epilepsy -- was developed by a multinational team who used more than 1,000 patient MRI scans from 22 international epilepsy centres.


Brain regions known as FCDs have evolved improperly and frequently lead to drug-resistant epilepsy. Surgery is usually used to treat it, however, finding the lesions on an MRI is a constant problem for doctors because MRI scans for FCDs can appear normal.

The scientists employed about 300,000 places throughout the brain to quantify cortical properties from the MRI scans, such as how thick or folded the cortex/brain surface was.

The system was then trained on cases that experienced radiologists had classified as either having FCD or being a healthy brain based on their patterns and attributes.

In general, the algorithm was successful in identifying the FCD in 67 per cent of instances in the cohort, according to the results, which were published in Brain.

Radiologists had previously been unable to uncover the abnormalities in 178 of the patients based on their MRI results; however, the MELD algorithm was able to detect the FCD in 63 per cent of these cases.

This is crucial because, if doctors can identify the anomaly in the brain scan, surgery to remove it could result in a recovery.

A severe neurological illness

Mathilde Ripart, a co-first author from the UCL Great Ormond Street Institute of Child Health, stated: "We focused on developing an AI system that was interpretable and could assist physicians in making decisions. A crucial step in that process was demonstrating to the doctors how the MELD algorithm generated its forecasts.

Dr Konrad Wagstyl, a co-senior author from the UCL Queen Square Institute of Neurology, added: "This algorithm might make it easier to identify these concealed lesions in epileptic children and adults, which would increase the number of patients who could potentially benefit from brain surgery to treat their condition and enhance cognitive function. In England, epilepsy surgery could help about 440 kids a year."

Epilepsy is a severe neurological illness that affects 1 per cent of the world's population and is marked by recurrent seizures.

About 600,000 people in the UK are impacted. The majority of epilepsy patients can be treated with pharmaceuticals, although 20-30 per cent of them do not benefit from them.

FCD is the most frequent cause in children who have had surgery to treat their epilepsy, and it is the third most frequent cause in adults.

Furthermore, FCD is the most frequent reason for epilepsy in people who have a brain anomaly that cannot be seen on an MRI scan.

The 22 hospitals involved in the study used various MRI scanners from around the world, making the algorithm more robust but also perhaps affecting its sensitivity and specificity.

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less